October 1, 2019

Update on progress in clinical lead program VP01 (C21)

Gothenburg, October 1, 2019 – Following the successful dose escalation phase I study, Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innova...
Read more
October 1, 2019

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

Paris, France, October 1, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering a...
Read more
October 1, 2019

Nordic Nanovector appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs

Oslo, Norway, 1 October 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs. Dr Elbl is a ph...
Read more
September 26, 2019

Patient recruitment in the Pivotal Phase 2-Study HORIZON completed

Stockholm – September 26, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clin...
Read more
September 25, 2019

Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company fo...
Read more
September 24, 2019

Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma

Oslo, Norway, 24 September 2019 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today ann...
Read more
September 23, 2019

GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Clinically meaningful improvement of 25 ETDRS letters equivalent versus nadir of BCVA in GS010-treated eyes at 96 weeks Results coherent with those of REVERSE: durable bilat...
Read more
September 19, 2019

Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities...
Read more
September 18, 2019

BONESUPPORT HOLDING AB presents health economic evidence

Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids announced...
Read more
September 17, 2019

Nordic Nanovector R&D Day unveils updates on several programs

17.09.2019 07:00 Clinical          LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complet...
Read more